Clinical trial
Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
NCT02113241 is registered in ClinicalTrials.gov with University of Guadalajara as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion
- Lead sponsor
- University of Guadalajara
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- April 30, 2014
- Completion date
- May 31, 2015
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metabolic syndrome x